For example, sorafenib, the first multi-tyrosine kinase inhibitor approved for diverse cancers and known to induce ferroptosis, has been found to enhance cuproptosis by increasing FDX1 aggregation and GSH depletion [73]. This evidence concerns the gene FDX1 and cancer.